Literature DB >> 33253347

Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report.

Kenkichiro Taira1, Kazunori Fujiwara1, Takahiro Fukuhara1, Tsuyoshi Morisaki1, Satoshi Koyama1, Ryohei Donishi1, Hiromi Takeuchi1.   

Abstract

Cetuximab is an effective drug used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma. Skin toxicities such as paronychia and skin exsiccation are common adverse events caused by cetuximab. Skin toxicities may cause significant physical and psychosocial discomfort. The goal of managing skin toxicities is to minimize the detrimental effects on quality of life and continue the treatment. In one patient, skin toxicities became severe, up to grade 2, during treatment. The pain induced by paronychia and skin exsiccation made daily life difficult. Ten days after starting Unseiin, symptoms and finger findings resolved significantly. The patient could resume daily activities. No adverse effects induced by Unseiin were observed during treatment. Unseiin was effective on paronychia and skin exsiccation in this case and may contribute to successful treatment of skin toxicities induced by cetuximab. ©2020 Tottori University Medical Press.

Entities:  

Keywords:  Kampo medicine; cetuximab; epidermal growth factor receptor inhibitor; paronychia skin toxicities

Year:  2020        PMID: 33253347      PMCID: PMC7683911          DOI: 10.33160/yam.2020.11.020

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  37 in total

1.  Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes.

Authors:  Toru Kono; Atsushi Kaneko; Chinami Matsumoto; Chika Miyagi; Katsuya Ohbuchi; Yasuharu Mizuhara; Kanako Miyano; Yasuhito Uezono
Journal:  Integr Cancer Ther       Date:  2014-02-04       Impact factor: 3.279

Review 2.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

3.  Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

Authors:  Weg M Ongkeko; Xabier Altuna; Robert A Weisman; Jessica Wang-Rodriguez
Journal:  Am J Clin Pathol       Date:  2005-07       Impact factor: 2.493

4.  Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from Scutellaria radix.

Authors:  Y S Chi; H P Kim
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-01       Impact factor: 4.006

5.  Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Authors:  Neelam T Shah; Mark G Kris; William Pao; Leslie B Tyson; Barbara M Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

6.  Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study.

Authors:  Erdinc Aygenc; Serdar Celikkanat; Mustafa Kaymakci; Ferdi Aksaray; Cafer Ozdem
Journal:  Otolaryngol Head Neck Surg       Date:  2004-03       Impact factor: 3.497

7.  Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study.

Authors:  Antonella Tosti; Bianca Maria Piraccini; Emanuela Ghetti; Maria Delia Colombo
Journal:  J Am Acad Dermatol       Date:  2002-07       Impact factor: 11.527

8.  Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study.

Authors:  D Rigopoulos; S Gregoriou; E Belyayeva; G Larios; G Kontochristopoulos; A Katsambas
Journal:  Br J Dermatol       Date:  2008-12-16       Impact factor: 9.302

9.  Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.

Authors:  Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Authors:  Sacha I Rothschild; Daniel Betticher; Reinhard Zenhäusern; Sandro Anchisi; Roger von Moos; Miklos Pless; Peter Moosmann; Razvan A Popescu; Antonello Calderoni; Marco Dressler; Daniel Rauch; Stefanie Pederiva; Regina Woelky; Claudia Papet; Vera Bühler; Markus Borner
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.